Bicycle Therapeutics plc (BCYC): Price and Financial Metrics
BCYC Stock Summary
- BCYC's went public 1.92 years ago, making it older than merely 3.06% of listed US stocks we're tracking.
- BCYC's price/sales ratio is 67.56; that's higher than the P/S ratio of 95.41% of US stocks.
- With a year-over-year growth in debt of 1,093.53%, BICYCLE THERAPEUTICS plc's debt growth rate surpasses 98.33% of about US stocks.
- If you're looking for stocks that are quantitatively similar to BICYCLE THERAPEUTICS plc, a group of peers worth examining would be CDXS, MYOV, FBIO, ZGNX, and QUIK.
- BCYC's SEC filings can be seen here. And to visit BICYCLE THERAPEUTICS plc's official web site, go to www.bicycletherapeutics.com.
BCYC Stock Price Chart Interactive Chart >
BCYC Price/Volume Stats
|Current price||$30.99||52-week high||$33.20|
|Prev. close||$31.20||52-week low||$12.54|
|Day high||$31.62||Avg. volume||174,464|
|50-day MA||$27.30||Dividend yield||N/A|
|200-day MA||$21.70||Market Cap||715.56M|
Bicycle Therapeutics plc (BCYC) Company Bio
Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
BCYC Latest News Stream
|Loading, please wait...|
BCYC Latest Social Stream
View Full BCYC Social Stream
Latest BCYC News From Around the Web
Below are the latest news stories about BICYCLE THERAPEUTICS plc that investors may wish to consider to help them evaluate BCYC as an investment opportunity.
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that for the first time, preclinical work describing the discovery of BT7480, a novel Nectin-4/CD137 tumor-targeted immune cell agonist (TICATM), will be presented virtually in a "New Drugs on the Horizon" session at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15, 2021. Additional work covering TICAs and Bicycle Toxin Conjugates® (BTCs), will also be covered in a late-breaking mini-symposium, as well as in five e-posters.
Strength Seen in Bicycle Therapeutics PLC Sponsored ADR (BCYC): Can Its 5.9% Jump Turn into More Strength?
Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Bicycle Therapeutics Announces Significant Progress Across Multiple Therapeutic Programs Beyond Oncology
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced progress updates for its Bicycle-based partnered programs outside of oncology.
Bicycle Therapeutics plc (NASDAQ:BCYC) Director Pierre Legault sold 7,784 shares of the firm’s stock in a transaction on Wednesday, March 17th. The stock was sold at an average price of $29.00, for a total value of $225,736.00. Following the transaction, the director now owns 7,784 shares in the company, valued at $225,736. The sale was […]
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bi
BCYC Price Returns